###begin article-title 0
Anaplastic lymphoma kinase: signalling in development and disease
###end article-title 0
###begin p 1
RTKs (receptor tyrosine kinases) play important roles in cellular proliferation and differentiation. In addition, RTKs reveal oncogenic potential when their kinase activities are constitutively enhanced by point mutation, amplification or rearrangement of the corresponding genes. The ALK (anaplastic lymphoma kinase) RTK was originally identified as a member of the insulin receptor subfamily of RTKs that acquires transforming capability when truncated and fused to NPM (nucleophosmin) in the t(2;5) chromosomal rearrangement associated with ALCL (anaplastic large cell lymphoma). To date, many chromosomal rearrangements leading to enhanced ALK activity have been described and are implicated in a number of cancer types. Recent reports of the EML4 (echinoderm microtubule-associated protein like 4)-ALK oncoprotein in NSCLC (non-small cell lung cancer), together with the identification of activating point mutations in neuroblastoma, have highlighted ALK as a significant player and target for drug development in cancer. In the present review we address the role of ALK in development and disease and discuss implications for the future.
###end p 1
###begin title 2
DISCOVERY OF THE ALK (ANAPLASTIC LYMPHOMA KINASE) RTK (RECEPTOR TYROSINE KINASE)
###end title 2
###begin p 3
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
ALK was originally described as a novel tyrosine phosphoprotein in ALCL (anaplastic large cell lymphoma) cell lines in 1994 [1,2]. The identity of this protein was revealed as a chimaeric protein created via a translocation event between chromosomes (2;5)(p23:q35), generating a previously uncharacterized fusion protein, NPM (nucleophosmin)-ALK. NPM-ALK contains the N-terminal portion of the NPM protein and the kinase domain of a then novel tyrosine kinase protein that was named ALK after the disease [1].
###end p 3
###begin title 4
STRUCTURAL FEATURES OF ALK
###end title 4
###begin p 5
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 738 739 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 740 741 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1078 1086 1078 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 505 510 <span type="species:ncbi:9606">human</span>
The intriguing characteristics of the full-length ALK RTK were not revealed until 1997, when they were simultaneously reported by two groups [3,4]. ALK displays the classical structural features of a RTK, with an extracellular ligand-binding domain, a transmembrane-spanning region and an intracellular tyrosine kinase domain. Based on overall homology, ALK is grouped with LTK (leucocyte tyrosine kinase), and together they form their own subgroup within the IR (insulin receptor) superfamily [3,4]. The human ALK gene encodes a protein of 1620 amino acids giving rise to a protein of approx. 180 kDa. However, as a result of post-translational modifications such as N-linked glycosylations, ALK migrates at approx. 220 kDa on SDS/PAGE [3,4]. The ALK extracellular region contains a unique combination of domains among the RTKs, exhibiting an N-terminal signal peptide, followed by two MAM (meprin, A5 protein and receptor protein tyrosine phosphatase mu) domains, an LDLa (low-density lipoprotein class A) motif and a large glycine-rich region proximal to the membrane [3-6] (Figure 1).
###end p 5
###begin title 6
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 34 39 <span type="species:ncbi:9606">human</span>
Domain structure of human ALK and human LTK
###end title 6
###begin p 7
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 414 419 <span type="species:ncbi:9606">human</span>
The N-terminal region of human ALK (hALK) comprises two MAM domains (amino acids 264-427 and 480-626), one LDLa domain (amino acids 453-471) and a glycine rich (G-rich) region (amino acids 816-940). A transmembrane (TM)-spanning segment, connects the extracellular region with the protein tyrosine kinase (PTK), domain (amino acids 1116-1383)-containing intracellular region. The closest family member, LTK [hLTK (human LTK)], is depicted with the corresponding regions denoted. The signal peptide (amino acids 1-16), the glycine rich, G-rich, domain (amino acids 63-334) and the kinase domain (amino acids 510-777) located in the intracellular C-terminal region of the protein.
###end p 7
###begin p 8
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 403 413 403 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 534 544 534 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 646 656 646 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1220 1224 1220 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1604</sup>
###xml 1275 1277 1275 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1280 1288 1280 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1467 1471 1467 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1278</sup>
###xml 1579 1583 1579 1583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1278</sup>
###xml 1719 1723 1719 1723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1278</sup>
###xml 1786 1788 1786 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1789 1791 1789 1791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 961 966 <span type="species:ncbi:10090">mouse</span>
###xml 971 976 <span type="species:ncbi:9606">human</span>
###xml 1106 1111 <span type="species:ncbi:10090">mouse</span>
###xml 1116 1121 <span type="species:ncbi:9606">human</span>
###xml 1170 1175 <span type="species:ncbi:9606">human</span>
Within ALK, the LDLa domain has an unknown function. However, this module mediates the binding between the LDL-receptor and LDL [7,8], suggesting a potential role in ligand binding for this domain of ALK. MAM domains are thought to participate in cell-cell interactions [9], but their significance for ALK function is unclear. The importance of the MAM domain is nevertheless emphasized in studies from Drosophila in which a point mutation altering a highly conserved aspartic acid residue in the MAM domain to arginine renders dALK (Drosophila ALK) inactive [10]. The functional significance of the glycine-rich domain has also been reported in Drosophila, where several loss-of-function dALK mutants display point mutations that convert a single glycine residue within the glycine-rich region into an acidic amino acid [10]. The domain organization of ALK is conserved throughout evolution, with the highest conservation found in the kinase domains. In fact, mouse and human ALK show 87% overall homology at the protein level, and within the kinase domain these differ at only four amino acids. Although mouse and human ALK are highly similar, it should be noted that human ALK contains one extra tyrosine residue, Tyr1604, which has been implicated in tumour progression [11] (Figure 2). Within the activation loop of the kinase domain, ALK contains a YxxxYY motif in common with the IR. It has been reported that phosphorylation of the first tyrosine residue (Tyr1278) of this YxxxYY motif is predominant in the autoactivation of the ALK kinase domain. Phosphorylation of Tyr1278 appears to be determined in part by the intervening RAS amino acid triplet in the activation loop (Y'RAS'YY), immediately following Tyr1278 of ALK, which differs from the activation loop of the IR RTK [12,13].
###end p 8
###begin title 9
Signalling via ALK
###end title 9
###begin p 10
Signalling via dALK occurs via binding of the ligand Jeb, downstream activation of ERK and transcription of downstream target genes. Signalling via mammalian ALK is thought to occur via ligand-mediated dimerization in response to the MK and PTN ligands. ALK mediates signalling via the JAK/STAT, RAS/MAPK, PI3K and PLCgamma pathways. Activation of ALK via RPTPbeta/zeta, independently of direct ALK-ligand interactions has also been proposed. Lastly, ALK is proposed to function as a dependency receptor which is cleaved by caspase 3 (Casp. 3) in the absence of ligand, thereby promoting apoptosis.
###end p 10
###begin title 11
ALK FUNCTION IN MODEL ORGANISMS
###end title 11
###begin title 12
dALK
###end title 12
###begin p 13
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 64 87 64 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 351 361 351 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 553 563 553 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 64 87 <span type="species:ncbi:7227">Drosophila melanogaster</span>
The In vivo function of ALK has been most thoroughly studied in Drosophila melanogaster where ALK was initially shown to drive ERK (extracellular-signal-regulated kinase) activation In vivo [5]. During embryonic development of the fruitfly, dALK plays a vital role in the formation of the visceral musculature of the gut [10]. In the absence of dALK, Drosophila embryos hatch into gut-less larvae, which consequently die. This phenotype is due to a lack of specification of a particular cell type, the founder cell, in the developing gut musculature of Drosophila embryos deficient in dALK signalling [14-16]. Activation of the dALK signal transduction pathway in wild-type flies is initiated by binding of the Jeb (jelly belly) ligand to a specific set of cells in the embryonic visceral mesoderm, which thereby are specified as founder cells. Founder cells then fuse with fusion competent myoblasts to give rise to the multinucleated visceral musculature of the gut [14-18]. Since dALK signalling specifies founder cells, loss of dALK results in an absence of founder cells, as well as muscle cell fusion, which as a consequence leads to defective assembly of a functional gut musculature in dALK mutant flies.
###end p 13
###begin p 14
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 667 675 667 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
The Jeb protein is now well-established as an activating ligand for dALK, and as such is also required for founder-cell specification [14-16]. Jeb is a secreted protein of approx. 61 kDa containing a secretory signal and an LDLa domain [19]. The interaction of Jeb and dALK appears to be mediated via the LDLa domain in Jeb, since a Jeb mutant protein lacking the LDLa domain is unable to bind dALK [15]. Activation of the Jeb/dALK signalling pathway leads to ERK activation and further downstream transcription of target molecules such as Duf (dumbfounded)/Kirre (kin of irregular chiasm) [14-16], Org [15], Hand [20] and Dpp (decapentaplegic) [21] in the fruitfly (Figure 2).
###end p 14
###begin p 15
###xml 72 82 72 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 300 302 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 435 445 429 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 479 489 473 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 851 853 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
The Jeb/dALK signalling pathway is also critical for development of the Drosophila embryonic endoderm in an indirect manner, since dALK activity in the visceral mesoderm is required for Dpp [TGFbeta (transforming growth factor beta)] transcription and subsequent signalling in the adjacent endoderm [21]. Moreover, dALK and Jeb play a central role acting as an anterograde signalling pathway mediating neuronal circuit assembly in the Drosophila visual system. In the developing Drosophila eye, dALK is expressed in, and required for, the targeting of neurons in the optic lobe, whereas Jeb is primarily produced by photoreceptor axons, functioning to control target selection of R1-R6 axons in the lamina and R8 axons in the medulla. Lack of either protein results in mistargeting of the R8 axons during later maturation of the optic lobe neuropile [22].
###end p 15
###begin title 16
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Caenorhabditis elegans</italic>
###xml 0 22 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
Caenorhabditis elegans ALK [SCD-2 (suppressor of constitutive dauer-2)]
###end title 16
###begin p 17
###xml 3 4 3 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elegans</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 114 124 114 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C. elegans</italic>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 482 492 482 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C. elegans</italic>
###xml 611 613 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 678 680 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 694 704 691 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 935 937 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 3 13 <span type="species:ncbi:6239">C. elegans</span>
###xml 114 124 <span type="species:ncbi:6239">C. elegans</span>
###xml 482 492 <span type="species:ncbi:6239">C. elegans</span>
In C. elegans, ALK has been implicated in neuronal control of entry into dauer and synapse stabilization [23,24]. C. elegans ALK (T10H9.2), now formally known as SCD-2, was identified as an effector through which the F-box protein Fsn-1 (F-box protein at the synapse-1) stabilizes synapse formation in GABAergic neuromuscular junctions [23]. More recently, SCD-2 mutants were characterized which display a temperature-sensitive adaptation to dauer entry [24]. Epistatic analysis in C. elegans suggests that SCD-2 modulates the TGFbeta pathway upstream of Daf3 (abnormal dauer formation 3; Smad)/Daf5 (Sno/Ski) [24]. The SCD-2 ligand has been identified as Hen-1 (hesitation-1) [25], which like Drosophila Jeb is a secreted ligand containing an LDLa domain, and the genetically mapped signal transduction pathway employs the adaptor SOC-1 (suppressor of Clr-1) and the MAPK (mitogen-activated protein kinase) SMA-5 (small body size-5) [24].
###end p 17
###begin title 18
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
Zebrafish LTK/ALK
###end title 18
###begin p 19
###xml 33 44 33 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Danio rerio</italic>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">shady</italic>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 23 32 <span type="species:ncbi:7955">zebrafish</span>
###xml 33 44 <span type="species:ncbi:7955">Danio rerio</span>
###xml 104 113 <span type="species:ncbi:7955">zebrafish</span>
###xml 316 325 <span type="species:ncbi:7955">zebrafish</span>
###xml 425 430 <span type="species:ncbi:10090">mouse</span>
###xml 435 440 <span type="species:ncbi:9606">human</span>
###xml 483 492 <span type="species:ncbi:7955">zebrafish</span>
###xml 629 634 <span type="species:ncbi:9606">human</span>
Elegant studies in the zebrafish Danio rerio have recently demonstrated an In vivo role for LTK. During zebrafish embryogenesis LTK signalling leads to specification of iridophores from the neural crest linage, and mutants in LTK (known as shady) display defects in pigmentation patterns [26]. The LTK/ALK family in zebrafish comprises two genes: LTK and ALK, both of which contain MAM domains [26]. This is in contrast with mouse and human LTK which both lack MAM domains. Although zebrafish LTK has no reported ligand to date, its expression in the developing neural crest is of particular interest given the recent reports of human ALK activating mutations in neuroblastoma (see below).
###end p 19
###begin title 20
MAMMALIAN ALK
###end title 20
###begin p 21
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 797 798 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1176 1177 1176 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 361 368 <span type="species:ncbi:9031">chicken</span>
###xml 599 602 <span type="species:ncbi:10116">rat</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 838 843 <span type="species:ncbi:9606">human</span>
###xml 913 918 <span type="species:ncbi:10090">mouse</span>
###xml 1104 1109 <span type="species:ncbi:9606">human</span>
Mammalian ALK has been postulated to play a role in the normal development and function of the nervous system, a hypothesis arising from the extensive expression of ALK mRNA throughout the nervous system during mouse embryogenesis [3,4,27]. Furthermore, this pattern of ALK mRNA expression is recapitulated in the developing CNS (central nervous system) of the chicken where ALK localizes to a subset of spinal motor neurons, the sympathetic ganglia and DRG (dorsal root ganglia) [28]. A similar pattern of expression in a subtype of DRG neurons during DRG development has also been reported in the rat [29]. In mice, the intensity of the ALK transcript and protein diminishes after birth, reaching minimum levels at 3 weeks of age, and is thereafter maintained at low levels in the adult animal [3]. Immunohistochemical studies of adult human tissue reveal a pattern consistent with that previously reported for mouse ALK, with a weak ALK signal observed in the CNS [30]. ALK mRNA transcripts of different sizes have also been reported in the testis, small intestine, colon, prostate and brain of adult human material, suggesting that differential splicing of ALK may occur [1].
###end p 21
###begin p 22
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1649 1651 1641 1643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
in vitro studies also support a role for ALK in neuronal development. For instance, substitution of the extracellular region of ALK with the mouse IgG Fc domain, resulting in the creation of a constitutively active membrane-bound ALK-IgG Fc hybrid protein, has the capacity to induce neuronal differentiation of PC12 cells. Inhibition of MEK (MAPK/ERK kinase) abolishes ALK-IgG Fc-induced PC12 cell neurite outgrowth, implying that neurite outgrowth activity is mediated via the MAPK pathway [31]. Other groups have also reported a role for ALK in neurite outgrowth in cell culture [32-35]. Moreover, employing antibodies to activate ALK, it has been shown that Shc (Src homology and collagen homology) association with ALK is required for downstream ERK1/2 activation and neurite extension, further strengthening the hypothesis that neuronal differentiation induced by ALK is mediated via the MAPK pathway [33,36]. FRS2 (fibroblast growth factor receptor substrate 2)/SNT has also been reported to bind both ALK and NPM-ALK [36,37]. Since prolonged activation of ERK is associated with differentiation of PC12 cells, FRS2 recruitment may contribute to the neuronal differentiation of PC12 cells stimulated by activated ALK [36]. Experiments replacing the extracellular domain of ALK with the extracellular region of the EGFR (epidermal growth factor receptor), leads to the phosphorylation of ALK and subsequent activation of PLCgamma (phospholipase Cgamma) and PI3K (phosphoinositide 3-kinase). Activation of chimaeric EGFR-ALK efficiently transforms NIH 3T3 cells, further illustrating the potential oncogenic properties of ALK when deregulated [38].
###end p 22
###begin title 23
LIGANDS OF MAMMALIAN ALK
###end title 23
###begin p 24
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 403 404 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 814 815 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 979 987 979 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 742 747 <span type="species:ncbi:9606">human</span>
In mammals PTN (pleiotrophin) also known as HB-GAM (heparin-binding growth-associated molecule) [39], OSF-1 (osteoblast-specific factor-1) [40], HARP (heparin affinity regulatory peptide) [41] and HBNF (heparin-binding neurotrophic factor) [42]; and MK (midkine) [43], also known as RIHB (retinoic acid-inducible heparin-binding protein) [44], have been postulated to be the activating ligands for ALK [6,45]. MK and PTN are small, heparin-binding growth factors implicated in diverse processes such as neural development, cell migration and angiogenesis [46,47]. The observation that PTN could function as a ligand for ALK arises from the isolation of a small portion of the extracellular region of ALK which was identified upon screening a human foetal brain phage display cDNA library for PTN-binding partners [6]. Subsequently, the PTN-related protein MK was identified as an ALK ligand. Furthermore, antibodies directed toward the ALK extracellular domain could inhibit the in vitro ligand-receptor interaction, suggesting that MK and PTN bind ALK [45].
###end p 24
###begin p 25
###xml 84 94 84 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 363 365 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 366 368 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 386 388 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 389 391 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 446 448 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 505 507 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 98 104 <span type="species:ncbi:9606">humans</span>
MK and PTN are conserved throughout evolution and are found in species ranging from Drosophila to humans [46]. The subject of receptors for MK and PTN is a complex one since, in addition to ALK, a number of other proposed receptors exist. To date, MK and PTN have been shown to bind and signal via RPTPbeta/zeta (receptor protein tyrosine phosphatase beta/zeta) [48,49] and N-syndecan [50,51], whereas MK can also bind LRP (LDL-related protein) [52] as well as the alpha4beta1- and alpha6beta1-integrins [53].
###end p 25
###begin p 26
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 819 821 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
Enhanced proliferation has been reported upon ALK activation via PTN [6,54], a function that seems to be dependent on PKB (protein kinase B)/Akt activation, thus implicating the PI3K pathway as a target of PTN-ALK signalling [54,55]. Moreover, a role for ALK in opposing apoptosis via the MAPK pathway in NIH 3T3 cells has been suggested [54]. In agreement, ribozyme-mediated reduction of ALK in glioblastoma cell lines results in increased apoptosis [55]. MK-ALK signalling has also been reported to be important for proliferation [45,56]. MK-mediated activation of ALK leads to IRS-1 (IR substrate-1) and Shc interaction, stimulating downstream signalling and ultimately activation of NF-kappaB (nuclear factor kappaB), thereby inducing cell growth, which is abrogated upon knockdown of the p65 subunit of NF-kappaB [56].
###end p 26
###begin p 27
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
Although several groups have shown that PTN and MK activate ALK [6,45,54-57] some questions remain, since a number of groups have reported contradictory findings [32,33,58-60]. Agonist monoclonal ALK antibodies mediate efficient ERK1/2 phosphorylation and differentiation of PC12 cells; however, this could not be reproduced with PTN which failed to induce phosphorylation of ALK [32]. Furthermore, treatment with independently developed ALK-activating antibodies stimulates neuronal differentiation of SK-N-SH cells, which can be blocked by the MEK inhibitor PD98059, thus implicating the MAPK pathway in this process. However, this activation of ALK was not reproduced when MK and PTN were employed [33].
###end p 27
###begin p 28
###xml 231 233 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 490 492 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
Interestingly, two different species of PTN, PTN15 and PTN18, have been described. PTN15 has been reported to promote glioblastoma growth via ALK, whereas PTN18 promoted glioblastoma migration in an RPTPbeta/zeta-dependent manner [57]. The existence of two different PTN isoforms has been hypothesized to explain the discrepancy in reports concerning the ability of PTN to activate ALK. However, some investigators have been unable to reproduce the effects of either PTN15 or PTN18 on ALK [59]. Thus the physiological significance of ALK activation via PTN and MK is still a matter of debate and investigation within the field.
###end p 28
###begin p 29
###xml 199 201 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 427 429 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
One hypothesis concerning ALK activation via PTN comes from the observation that PTN can indirectly lead to phosphorylation of ALK via binding to, and inactivation of, the phosphatase RPTPbeta/zeta [61]. In this scenario, phosphorylation of ALK is independent of the ALK extracellular region, since a membrane-bound construct containing the ALK intracellular region is phosphorylated as effectively as the full-length protein [61].
###end p 29
###begin p 30
###xml 74 84 74 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C. elegans</italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B64">64</xref>
###xml 350 360 350 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 448 450 448 450 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mi</underline>
###xml 460 463 460 463 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ple</underline>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B65">65</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B65">65</xref>
###xml 74 84 <span type="species:ncbi:6239">C. elegans</span>
MK and PTN display no obvious homology toward the dALK ligand Jeb, or the C. elegans ligand Hen-1 [19,25]. Jeb harbours a signal peptide and an LDLa domain [19], whereas MK and PTN are composed of two domains, one N-terminal N-domain and one C-terminal C-domain [62,63], which contain heparin-binding modules important for their activity [63,64]. In Drosophila the homologues for MK and PTN are the orphan ligands Miple1 and Miple2 (where Miple is Midkine and Pleiotrophin) [65]. Although the combined expression pattern of Miple1 and Miple2 complement the expression pattern of dALK, suggesting that a role as activating ligands for dALK is possible, this has yet to be tested at the gene level [65].
###end p 30
###begin p 31
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 446 454 446 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 505 512 505 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
Finally, a novel dependence receptor function for ALK has recently been reported, suggesting that ALK may have an activation independent function [60]. In this study [60], cleavage of ALK by caspase 3 was found to expose a pro-apoptotic intracellular domain of ALK, resulting in increased apoptosis in Jurkat and 13.S.1.24 cells treated with apoptosis-inducing agents. Moreover, this pro-apoptotic function was counteracted by activation of ALK (Figure 2). The relevance of these intriguing results in an In vivo context remains to be explored.
###end p 31
###begin title 32
ALK IN THE MOUSE
###end title 32
###begin p 33
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B66">66</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B67">67</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B67">67</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B68">68</xref>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
Throughout the literature a number of comments have been made regarding ALK mutant mice generated by the Morris group, stating that they are viable without any gross alterations [66]. This is in agreement with observations from the Palmer and Hallberg groups, who have also generated ALK mutant mice (E. Vernersson, R.H. Palmer and B. Hallberg, unpublished work). A recent study describes a third independently generated mouse ALK knockout, which displays increased hippocampal progenitor proliferation, increased performance in hippocampal-associated tasks, as well as increased levels of dopamine within the basal cortex [67]. Interestingly, the authors observed an increase in the number of calretinin-positive cells within the hippocampus, a phenotype also noted in MK-knockout animals [67,68].
###end p 33
###begin p 34
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B69">69</xref>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B72">72</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B73">73</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B74">74</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B75">75</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B76">76</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B67">67</xref>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B77">77</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B76">76</xref>
###xml 1027 1028 1027 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1029 1030 1029 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1270 1278 1270 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1362 1369 1362 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 848 853 <span type="species:ncbi:10090">mouse</span>
###xml 1312 1317 <span type="species:ncbi:10090">mouse</span>
MK and PTN exhibit similar expression patterns in rodents [69-72], and studies of MK mutant mice embryos, which display a strong up-regulation of PTN expression, suggest that PTN and MK are functionally redundant [73]. Indeed, the MK/PTN double mutant shows a more severe phenotype than either of the single knockouts. These phenotypes include female infertility [74] and hearing impairments [75]. The closest ALK relative, LTK, is expressed in pre-B-cells and adult neurons in the hippocampus and cerebral cortex [76]. Given that the ALK mutant phenotype is hippocampus related, the idea that LTK might compensate for ALK loss is intriguing and relevant [67]. It is known that LTK is able to promote neuronal differentiation of PC12 cells, underscoring the fact that ALK and LTK may potentially compensate for one another [77]. Thus far, however, mouse LTK appears only to be expressed in the adult and not during development [76], suggesting a clear distinction from ALK, which is extensively expressed during embryogenesis [3,4,27]. Furthermore, whereas LTK and ALK share a highly similar intracellular tyrosine kinase domain, there are notable differences in the extracellular region, with LTK lacking several domains found in ALK, such as the MAM and LDLa domains (Figure 1). To date, there is no published mouse LTK knockout to suggest a role for this RTK In vivo, and therefore the question of whether or not LTK might substitute for loss of ALK must await future investigation.
###end p 34
###begin title 35
ALK IN HUMANS
###end title 35
###begin p 36
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1058 1065 1058 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human ALK appears to exist as a 140 kDa protein, as well as the 220 kDa full-length ALK species [3]. The 140 kDa ALK species is thought to be the result of a cleavage within the extracellular region of full-length ALK, generating an 80 kDa form of unknown function [32]. The 140 kDa ALK protein is phosphorylated in response to activation of ALK [33,36,59]. In addition, the presence of an 85 kDa ALK protein which is phosphorylated in response to activating ALK antibodies has been observed in NIH 3T3 cells expressing full-length ALK [33]. Interestingly, a recent report suggests that an as yet unidentified factor secreted by Schwann cells can prevent ALK cleavage [29]. As yet no physiological function has been reported for these shorter ALK variants, and it is possible that the shorter forms of ALK are generated after activation of the receptor as part of down-regulation/degradation processes within the cell. However, future studies should lead to the definition of the cleavage sites, as well as the functional relevance of these forms of ALK In vivo.
###end p 36
###begin title 37
ALK IN DISEASE
###end title 37
###begin p 38
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B78">78</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B79">79</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B82">82</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B83">83</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B84">84</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B92">92</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B93">93</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Since the initial discovery of the NPM-ALK fusion protein in patients suffering from ALCL [1,2], ALK fusion proteins have also been described in IMTs (inflammatory myofibroblastic tumours) [78], NSCLC (non-small cell lung cancer) [79,80], DLBCLs (diffuse large B-cell lymphomas) [81], and SCC (squamous cell carcinoma) of the oesophagus [82,83]. Furthermore, full-length ALK has also been reported to be expressed in cell lines and tumours suggesting oncogenic progression via overexpression [30,55,58,84-92] or gain-of-function mutations, as has recently has been reported in cases of neuroblastoma [93-97].
###end p 38
###begin title 39
ALCL
###end title 39
###begin p 40
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B98">98</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B99">99</xref>
###xml 386 389 386 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B101">101</xref>
###xml 623 626 623 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B101">101</xref>
###xml 627 630 627 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B105">105</xref>
###xml 707 710 707 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B101">101</xref>
###xml 805 808 805 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B103">103</xref>
###xml 1111 1114 1111 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B103">103</xref>
###xml 1115 1118 1115 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B105">105</xref>
###xml 1119 1122 1119 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B106">106</xref>
###xml 269 277 <span type="species:ncbi:9606">children</span>
###xml 373 381 <span type="species:ncbi:9606">children</span>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
###xml 680 688 <span type="species:ncbi:9606">children</span>
###xml 792 799 <span type="species:ncbi:9606">patient</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
ALK has been most extensively studied in the context of ALCL, a disease first described in 1985 [98]. ALCL is a non-Hodgkin's lymphoma arising from T-cells, and is characterized by the expression of CD30. ALK-positive ALCL is most commonly observed in young adults and children, accounting for 3% of adult non-Hodgkin's lymphoma and 10-30% of all non-Hodgkin's lymphoma in children [99-101]. ALK expression is an important prognostic factor used to predict clinical outcome for patients presenting with ALCL, since ALK-positive patients have a significantly higher 5-year survival rate as compared with ALK-negative cases [101-105]. ALK-positive ALCL occurs to a higher extent in children and young adults [101]; however, ALK expression in ALCL is a positive prognostic factor independent of patient age [103]. Currently, combinatorial chemotherapy treatment, CHOP [cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine) and prednisone] is applied for treatment of ALCL patients as a first approach. In addition, radiation therapy can be employed as an important complement to CHOP therapy [103,105,106]. Currently, there is no treatment for ALK-positive ALCL aimed at directly targeting ALK.
###end p 40
###begin p 41
###xml 191 194 191 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B107">107</xref>
###xml 437 440 437 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B108">108</xref>
###xml 453 456 453 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B109">109</xref>
###xml 479 482 479 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B110">110</xref>
###xml 695 698 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B110">110</xref>
###xml 1013 1016 1013 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B111">111</xref>
Besides ALK, active caspase 3 expression is also used as a prognostic indicator for favourable outcome in ALCL. In fact, caspase 3 activity is strongly correlated with the expression of ALK [107]. The presence of STAT3 (signal transducer and activator of transcription 3) in both ALK-positive and ALK-negative ALCL has led to the suggestion that activated STAT3 may be a negative prognostic factor independent of ALK expression in ALCL [108]. Survivin [109] and MUC-1 (mucin-1) [110] are two additional markers that indicate a poorer outcome in ALCL regardless of ALK status. Within ALK-positive ALCL, expression of MUC-1 is indicative of a poorer prognosis with a decrease in overall survival [110]. The exact mechanism of MUC-1 in the modulation of ALK-positive ALCL is not fully understood. However, MUC-1 is commonly overexpressed in oncogenic processes, and via its adhesive properties is thought to modulate both metastatic capacity and provide hindrance for immune cells trying to access the tumour cells [111].
###end p 41
###begin p 42
###xml 193 196 193 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B112">112</xref>
###xml 273 276 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B113">113</xref>
There have been a number of intriguing reports concerning expression of ALK-fusion proteins in healthy individuals. Indeed, NPM-ALK transcripts have been detected in blood from healthy donors [112], as well as in healthy lymphoid tissue via RT (reverse transcriptase)-PCR [113]. Such reports raise the relevant question of whether the fusion transcript on its own is enough for inducing oncogenic transformation or whether secondary events are also required.
###end p 42
###begin title 43
ALK fusion proteins in ALCL
###end title 43
###begin p 44
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 382 385 382 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B114">114</xref>
###xml 568 571 568 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B115">115</xref>
###xml 572 575 572 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B116">116</xref>
###xml 737 740 737 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B116">116</xref>
###xml 975 978 975 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B116">116</xref>
In ALCL the kinase domain of ALK is fused to NPM, creating the constitutively expressed fusion protein NPM-ALK [1]. NPM is a multifunctional protein which serves as a molecular chaperone involved in the shuttling of pre-ribosome subunits from the nucleus to the cytoplasm during ribosome biogenesis, in addition to playing a role in DNA repair, transcription and genomic stability [114]. In the NPM-ALK fusion protein, oligomerization mediated via NPM juxtaposes two ALK tyrosine kinase domains, resulting in autophosphorylation and activation of ALK kinase activity [115,116]. The subcellular localization of NPM-ALK, which is present both in the cytoplasm and the nucleus, seems not to be critical for NPM-ALK-mediated transformation [116]. Besides the dimerization ability of NPM, the kinase activity of NPM-ALK is an absolute requirement for transforming activity, since mutation of the ATP-binding site (K219R) renders NPM-ALK kinase dead and eliminates transformation [116].
###end p 44
###begin p 45
###xml 143 146 143 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B117">117</xref>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B118">118</xref>
###xml 175 178 175 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B119">119</xref>
###xml 195 198 195 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B120">120</xref>
###xml 235 238 235 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B121">121</xref>
###xml 239 242 239 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B123">123</xref>
###xml 336 339 336 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B124">124</xref>
###xml 340 343 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B126">126</xref>
###xml 384 387 384 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B127">127</xref>
###xml 422 425 422 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B128">128</xref>
###xml 428 435 428 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
In addition to NPM, numerous other fusion partners exist for ALK in ALCL namely ALO17 (ALK lymphoma oligomerization partner on chromosome 17) [117], TFG (TRK-fused gene) [118,119], MSN (moesin) [120], TPM3 and 4 (tropomyosin 3 and 4) [121-123], ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase) [124-126], MYH9 (non-muscle myosin heavy chain) [127] and CLTC (clathrin heavy chain) [128] (Table 1). These fusion partner proteins of ALK share several common characteristics: (i) the transcription of the fusion protein is driven via the promoter of the ALK partner protein; (ii) the localization of the fusion protein is determined by the ALK partner protein and; (iii) oligomerization via the ALK partner protein induces autophosphorylation and thereby activation of the ALK kinase domain.
###end p 45
###begin title 46
Fusion partners of ALK in disease
###end title 46
###begin p 47
###xml 164 167 164 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B115">115</xref>
###xml 168 171 168 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B116">116</xref>
###xml 315 318 311 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B121">121</xref>
###xml 333 336 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B119">119</xref>
###xml 386 389 382 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B129">129</xref>
###xml 467 470 463 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B124">124</xref>
###xml 471 474 467 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B126">126</xref>
###xml 884 887 880 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B128">128</xref>
###xml 1121 1124 1117 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B120">120</xref>
###xml 1359 1366 1355 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1541 1544 1537 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B127">127</xref>
As discussed above, NPM is responsible for the dimerization essential for autophosphorylation of, and downstream signalling via the NPM-ALK tyrosine kinase domain [115,116]. The TPM3 and TFG fusion partners contain dimeric alpha-coiled-coil structures that are hypothesized to mediate the dimerization of TPM3-ALK [121] and TFG-ALK [119] respectively. Since ATIC exists as a homodimer [129], this property is assumed to be responsible for the activation of ATIC-ALK [124-126]. For MSN, MYH9 and CLTC, the means of dimerization seems to be more complex. It is believed that clathrin coat formation activates the kinase domain of ALK via the close proximity of the CLTC-ALK fusion proteins, since CLTC is a component of clathrin-coated vesicles. In agreement with this suggestion, CLTC-ALK is localized in a punctuated pattern within the cell, consistent with clathrin-coated vesicles [128]. The theory of 'close proximity' as a means of activating the ALK tyrosine kinase domain also applies to MSN-ALK, which is thought to be activated via the ability of MSN to crosslink the plasma membrane with the actin cytoskeleton [120]. Myosin heavy chain is also known to form a dimer, however the MYH9 sequence that is fused to ALK is missing the dimerization domain present in the full-length protein. In spite of this, the MYH9-ALK fusion protein is phosphorylated In vivo, indicating either an uncharacterized dimerization domain or that MYH9 potentially interacts with other proteins leading to multimerization and consequent activation of ALK [127].
###end p 47
###begin title 48
Oncogenic signalling via ALK-fusion proteins
###end title 48
###begin p 49
###xml 414 416 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 487 495 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 516 519 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">664</sup>
###xml 541 545 529 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1604</sup>
###xml 575 579 563 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1604</sup>
###xml 849 851 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 549 554 <span type="species:ncbi:9606">human</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
###xml 615 620 <span type="species:ncbi:10090">mouse</span>
The most studied ALK-fusion protein, NPM-ALK, signals via the PLCgamma, PI3K, RAS/MAPK and JAK (Janus kinase)/STAT pathways. PLCgamma has been shown to directly interact with NPM-ALK via its SH2 (Src homology 2) domain. This interaction is of importance for the transforming potential of NPM-ALK, since mutation of the NPM-ALK/PLCgamma interaction site abrogates transformation in transfected cell culture models [11]. A systematic analysis of NPM-ALK tyrosine to phenylalanine mutants (Figure 3), has identified Tyr664 (corresponding to Tyr1604 in human full-length ALK; Tyr1604 is present in human ALK but not in mouse ALK) as responsible for the PLCgamma interaction. Interestingly, all other mutants (except the kinase dead Y338F, Y342F and Y343F mutants) retained their ability to confer IL-3 (interleukin-3)-independent growth of Ba/F3 cells [11], indicating a key role for the PLCgamma pathway in ALK-dependent transformation.
###end p 49
###begin title 50
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
Tyrosine residues phosphorylated in the intracellular regions of human and mouse ALK
###end title 50
###begin p 51
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 257 261 257 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1604</sup>
###xml 433 436 433 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B166">166</xref>
###xml 580 584 576 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1604</sup>
###xml 595 597 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 608 612 604 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1507</sup>
###xml 623 626 619 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B115">115</xref>
###xml 637 641 633 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1358</sup>
###xml 652 655 648 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B157">157</xref>
###xml 668 672 664 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1096</sup>
###xml 683 686 679 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B115">115</xref>
###xml 700 704 696 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1096</sup>
###xml 712 716 708 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1507</sup>
###xml 727 729 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
###xml 155 160 <span type="species:ncbi:9606">human</span>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
The intracellular regions of human and mouse ALK (hALK and mALK respectively) contain the PTK domain. Potential autophosphorylation sites are shown within human and mouse ALK [11]. Note that there is no equivalent tyrosine residue in mouse ALK for human Tyr1604. Tyrosine residues within the activation loop are shown in bold. In italics is a profiling of putative phosphorylated tyrosine residues in NPM-ALK from ALCL cancer cells [166]. Four tyrosine sites, marked with*, have been tested by mutagenesis in NPM-ALK for interaction with signalling proteins such as PLC-gamma (Tyr1604 in hALK) [11], Shc (Tyr1507 in hALK) [115], Src (Tyr1358 in hALK) [157], IRS-1 (Tyr1096 in hALK) [115] and SNT (Tyr1096 and Tyr1507 in hALK) [37]. Localization of tyrosine residues within the intracellular region is not to scale. TM, transmembrane domain.
###end p 51
###begin p 52
###xml 169 172 169 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B130">130</xref>
###xml 280 283 280 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B130">130</xref>
###xml 284 287 284 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B131">131</xref>
###xml 477 480 477 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B130">130</xref>
###xml 481 484 481 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B132">132</xref>
###xml 800 803 800 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B132">132</xref>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
NPM-ALK interacts with PI3K thereby activating the catalytic subunit of PI3K, and leading to the phosphorylation of PKB/Akt and subsequent downstream signalling events [130]. This interaction has been reported to occur via both the SH2 and SH3 domains of the p85 subunit of PI3K [130,131]. Furthermore, an indirect interaction of p85 and NPM-ALK via other adaptor molecules must also be considered. Inactivation of the PI3K pathway induces apoptosis in NPM-ALK-positive cells [130,132], indicating a role for the PI3K/PKB/Akt pathway in anti-apoptotic signalling. Moreover, PKB/Akt activation appears to be critical for transformation by NPM-ALK, since mice inoculated with NPM-ALK-positive cells expressing a dominant-negative PKB/Akt display impaired oncogenic growth and delayed tumour formation [132].
###end p 52
###begin p 53
###xml 359 363 359 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kip1</sup>
###xml 364 367 364 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B133">133</xref>
###xml 505 509 505 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kip1</sup>
###xml 553 556 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B134">134</xref>
###xml 768 771 768 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B135">135</xref>
###xml 896 899 896 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B136">136</xref>
NPM-ALK regulates the FOXO3a (forkhead box O 3a) transcription factor via the PI3K/PKB/Akt pathway. Active PKB/Akt phosphorylates FOXO3a, leading to retention of FOXO3a in the cytoplasm. This has been shown to result in alterations at the level of transcription of several FOXO3a target genes in NPM-ALK-expressing lymphoma, including cyclin D2, Bin-1 and p27kip1[133]. In agreement, inactivation of PKB/Akt activity in ALCL cell lines, employing small molecule inhibitors, results in up-regulation of p27kip1 levels and induction of cell-cycle arrest [134]. An additional target for PI3K/PKB/Akt signalling in ALK-positive ALCL cell lines is mTOR (mammalian target of rapamycin), which displays reduced levels of phosphorylation in response to inhibition of PKB/Akt [135]. In addition, the RAS/MAPK pathway has also been reported to be important for mTOR activation in NPM-ALK-expressing cells [136].
###end p 53
###begin p 54
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B115">115</xref>
###xml 350 353 350 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B115">115</xref>
###xml 432 435 432 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B137">137</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B138">138</xref>
###xml 690 693 690 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B138">138</xref>
NPM-ALK interacts with IRS-1, Shc and Grb2 (growth-factor-receptor-bound protein 2), thus implicating the RAS/MAPK pathway as a downstream target of NPM-ALK activity [115]. Interaction with IRS-1 and Shc are non-essential for transformation, given that NPM-ALK mutants unable to interact with Shc and IRS-1 are still able to transform NIH 3T3 cells [115]. Previous reports suggest that NPM-ALK may be able to activate MEK directly [137,138]. Furthermore, simultaneous depletion of ERK1 and ERK2 impairs cell proliferation, whereas ERK1 depletion alone induces apoptosis in an ALCL-derived ALK-positive cell line, indicating that ERK1/2 are involved in survival and pro-apoptotic functions [138].
###end p 54
###begin p 55
###xml 191 194 191 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B139">139</xref>
###xml 195 198 195 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B141">141</xref>
###xml 316 319 316 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B142">142</xref>
###xml 320 323 320 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B144">144</xref>
###xml 447 450 447 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B140">140</xref>
###xml 451 454 451 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B145">145</xref>
###xml 651 654 651 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B145">145</xref>
###xml 655 658 655 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B146">146</xref>
###xml 867 874 867 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 876 879 876 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B147">147</xref>
###xml 1081 1084 1081 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B143">143</xref>
###xml 1085 1088 1085 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B145">145</xref>
###xml 1089 1092 1089 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B148">148</xref>
###xml 1093 1096 1093 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B149">149</xref>
###xml 1227 1234 1227 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1236 1239 1236 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B150">150</xref>
The last major pathway engaged by NPM-ALK is the JAK/STAT pathway. Several reports have demonstrated a correlation between NPM-ALK expression and STAT3 phosphorylation status and activation [139-141]. In agreement, inactivation of NPM-ALK with small molecule ALK inhibitors results in reduced STAT3 phosphorylation [142-144]. The observed interaction of NPM-ALK with JAK3, the receptor-associated tyrosine kinase responsible for STAT3 activation [140,145], provides a possible explanation for the effect of NPM-ALK on STAT3, given that inhibition of JAK3 leads to a reduction of STAT3 activation by NPM-ALK together with increased cellular apoptosis [145,146]. Although the precise mechanism of NPM-ALK induced activation of STAT3 is still a matter of investigation, it is clear that JAK3 activity is strongly associated with ALK expression and STAT3 phosphorylation In vivo [147]. It is also clear that down-regulation of active STAT3 is incompatible with the ALK-positive ALCL-transforming phenotype, as STAT3 compromised cells display increased apoptosis and cell-cycle arrest [143,145,148,149]. This finding is further supported by gene-targeting experiments which support a role for STAT3 in NPM-ALK-induced tumour growth In vivo [150].
###end p 55
###begin p 56
###xml 273 276 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B151">151</xref>
###xml 410 413 410 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B149">149</xref>
###xml 567 570 567 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B141">141</xref>
Several groups have provided additional information concerning the importance of the JAK/STAT pathway in ALCL. Loss of the JAK/STAT pathway negative regulator Shp1 (SH2 domain-containing phosphatase 1) as a result of DNA methylation has been reported in ALK-positive ALCL [151]. Indeed, restoring Shp1 levels in NPM-ALK-expressing cell lines inactivates the JAK/STAT pathway and blocks cell-cycle progression [149]. In addition, protein phosphatase 2A, a STAT3-interacting protein necessary for sustained STAT3 phosphorylation, is overexpressed in ALK-positive ALCL [141].
###end p 56
###begin p 57
###xml 210 213 210 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B140">140</xref>
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B141">141</xref>
###xml 291 294 291 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B152">152</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B152">152</xref>
###xml 806 809 806 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B153">153</xref>
Another member of the STAT family, STAT5, plays a less clear role in the pathogenesis of ALK-positive ALCL. Although several reports have been unable to detect activation of STAT5 in ALK-expressing cell lines [140,141], an interaction between STAT5B and NPM-ALK has been observed by others [152]. Furthermore, expression of dominant-negative STAT5B induces apoptosis and cell-cycle arrest in ALCL-derived cell lines expressing NPM-ALK [152]. In ALK-positive ALCL cell lines, STAT5A is silenced via methylation in a STAT3-dependent manner. Up-regulation of STAT5A by inhibition of methylation, results in decreased transcription of NPM-ALK due to the ability of STAT5A to interact with the NPM-ALK promoter region, indicating a tumour suppressor function for STAT5A in ALK-positive ALCL-derived cell lines [153]. Future investigations should clarify the role of STAT5A and B in NPM-ALK-induced tumorigenesis.
###end p 57
###begin p 58
###xml 275 278 275 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B154">154</xref>
###xml 279 282 279 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B155">155</xref>
###xml 368 371 368 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B154">154</xref>
###xml 602 605 602 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B154">154</xref>
###xml 696 699 696 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B156">156</xref>
###xml 840 843 840 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B157">157</xref>
Besides the above mentioned players there are a number of other proteins implicated in NPM-ALK-mediated malignancy. The small GTPases Rac1 (ras-related C3 botulinium toxin substrate 1) and Cdc42 (cell division cycle 42) are regulated by NPM-ALK in ALCL and other cell lines [154,155]. Furthermore, upon depletion of Cdc42, cell-cycle arrest and apoptosis are induced [154]. In addition, loss of p130Cas (Crk-associated substrate) modifies cell shape and inhibits cellular transformation by NPM-ALK. This dependency on p130Cas has been suggested to be modulated via Grb2 in NPM-ALK-positive ALCL cells [154]. Moreover, knockdown of Shp2 reduces the migratory capacity of cells expressing NPM-ALK [156] and Src kinases, in particular pp60Src, have been suggested to be important for the proliferative capacity of NPM-ALK-positive ALCL cells [157].
###end p 58
###begin p 59
###xml 377 381 377 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NIPA</sup>
###xml 535 538 535 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B158">158</xref>
###xml 865 868 865 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B159">159</xref>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast two-hybrid screening has led to the identification of NIPA (nuclear interacting partner of ALK) as a novel downstream target of NPM-ALK that has been shown to interact with NPM-ALK, as well as other ALK fusions, in a tyrosine kinase-dependent manner. NIPA has been characterized as an F-box-containing protein that defines the multisubunit ubiquitin E3 ligase complex SCFNIPA (where SCF is stem cell factor), which targets nuclear cyclin B1 for ubiquitination during interphase, thus contributing to the timing of mitotic entry [158]. Overexpression of NIPA protects Ba/F3 cells from apoptosis induced by IL-3 withdrawal. Furthermore, apoptosis triggered by wortmannin treatment in NPM-ALK-transformed Ba/F3 cells is enhanced by overexpression of dominant-negative NIPA mutants, implying an anti-apoptotic role for NIPA in NPM-ALK-mediated signalling events [159].
###end p 59
###begin p 60
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B160">160</xref>
###xml 596 599 596 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B161">161</xref>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 499 504 <span type="species:ncbi:9606">human</span>
Activation of JNK (c-Jun N-terminal kinase) in ALK-transformed cells has also been reported. Utilizing the Vav promoter to drive NPM-ALK expression in mice results in development of lymphomas which display a robust increase in JNK phosphorylation relative to controls [160]. Subsequent work has reported activation of JNK and c-Jun in ALCL cell lines as well as primary tumour cells. Similar activation was also observed upon introduction of NPM-ALK, but not a kinase-dead mutant NPM-ALK, into HEK (human embryonic kidney)-293T cells, suggesting that NPM-ALK is indeed capable of activating JNK [161].
###end p 60
###begin p 61
###xml 93 96 93 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B162">162</xref>
###xml 425 428 425 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B162">162</xref>
Elevation of SHH (sonic hedghog) expression in ALK-positive ALCL has recently been reported [162]. This increase of SHH expression is apparently dependent on NPM-ALK-induced PI3K activity, since inhibition of PI3K leads to a concentration-dependent decrease of SHH protein levels. Inhibition of SHH pathway activity results in decreased cell viability, colony formation and cell-cycle arrest in ALK-positive ALCL cell lines [162].
###end p 61
###begin p 62
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 91 94 91 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B137">137</xref>
###xml 95 98 95 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B163">163</xref>
###xml 99 102 99 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B168">168</xref>
###xml 466 469 466 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B166">166</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 1004 1007 1004 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B137">137</xref>
###xml 1207 1210 1207 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B163">163</xref>
###xml 1550 1553 1544 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B164">164</xref>
###xml 1768 1771 1759 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B165">165</xref>
###xml 1943 1946 1934 1937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B168">168</xref>
A number of studies have used high-throughput approaches to identify novel ALK targets [80,137,163-168]. Immunoprecipitation of phosphotyrosine peptides from ALCL cell extracts followed by LC-MS/MS (liquid chromatography tandem MS) analysis identifies ALK as the sole tyrosine kinase phosphorylated within the activation loop, together with tyrosine phosphorylated signalling molecules such as dok2 (docking protein 2), IRS-1, Shc, Crk, CrkL and STAT3 among others [166]. A similar global survey of phosphotyrosine signalling in lung cancer found up-regulation and activation of full-length ALK, and independently identified the EML4 (echinoderm microtubule-associated protein like 4)-ALK oncogene, as well as identifying a number of potential ALK downstream signalling proteins [80]. Immunoprecipitation of NPM-ALK from the Karpas 299 cell lines with monoclonal and polyclonal antibodies led to the identification of 36 NPM-ALK binding partners, including both known and novel ALK-interacting proteins [137]. Recent results employing a proteomics approach with NPM-ALK have moreover defined a set of phosphorylated proteins, including VASP (vasodilator-stimulated phosphoprotein) and ATIC, as ALK targets [163]. In addition, analysis of the transcriptomes of ALCL cell lines has established a number of ALK-regulated genes, including the transcription factor C/EBPbeta (CCAAT/enhancer-binding protein beta) and the anti-apoptotic protein BCL2A1 (B-cell lymphoma 2A1) which are required to sustain the growth and survival of ALK-positive ALCL cells [164]. A further study comparing ALK-positive and ALK-negative ALCL led to the identification of a number of ALK transcriptional targets, of which BCL-6, serpinA1 and C/EBPbeta were also confirmed at the protein level [165]. Finally, using a tandem-affinity purification approach several novel interaction partners for ALK were isolated including MCM6, MSH2, Nup98, Importin 8, 82Fip and Bag2 [168].
###end p 62
###begin p 63
###xml 346 349 346 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B125">125</xref>
###xml 393 396 389 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B118">118</xref>
None of the other known ALK-fusion proteins have been studied as extensively as NPM-ALK with respect to downstream signalling. Nevertheless they are assumed to function in a similar manner as NPM-ALK. This assumption is supported by studies on the ATIC-ALK and TFG-ALK fusion proteins, in which ATIC-ALK was shown to associate with Grb2 and Shc [125], and TFG-ALK with Grb2, Shc and PLCgamma [118].
###end p 63
###begin p 64
###xml 110 117 110 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 122 130 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 220 228 220 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 517 520 517 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B169">169</xref>
###xml 603 610 603 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 749 752 749 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B169">169</xref>
###xml 1093 1096 1093 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B108">108</xref>
###xml 1257 1260 1257 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B169">169</xref>
###xml 1261 1264 1261 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B170">170</xref>
###xml 355 364 <span type="species:ncbi:10090">nude mice</span>
###xml 894 901 <span type="species:ncbi:9606">patient</span>
An extensive evaluation of the oncogenic potential of NPM-ALK, TPM3-ALK, TFG-ALK, CLTLC-ALK and ATIC-ALK both In vivo and in vitro suggests that TPM3-ALK-expressing cells display a higher migratory and invasive capacity in vitro as compared with the other ALK-fusion proteins examined. However, when grafting transfected NIH 3T3 cells subcutaneously into nude mice, NPM-ALK- and TFG-ALK-mediated tumours were readily detected 6 days after inoculation, whereas TPM3-ALK-induced tumours were detected a few days later [169]. The invasive properties of the ALK-fusion proteins were further evaluated by an In vivo lung metastasis assay, in which TPM3-ALK displayed an increased capacity to form metastases in comparison with other ALK-fusion proteins [169]. However, whether this increased ability of TPM3-ALK-transfected cells to induce metastases has clinical relevance is currently unclear. In patient samples, the observation that activated STAT3 is expressed in 84% of ALK-positive ALCL cases has been speculated to be due to differences in signalling via the different ALK-fusion proteins [108]. Indeed, this hypothesis is supported by reports of efficient STAT3 phosphorylation in cells by NPM-ALK, TPM3-ALK, TFG-ALK and ATIC-ALK, but not by CLTLC-ALK [169,170].
###end p 64
###begin title 65
IMT
###end title 65
###begin p 66
###xml 133 136 133 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B171">171</xref>
###xml 357 360 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B172">172</xref>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B171">171</xref>
###xml 506 509 506 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B173">173</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B78">78</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B78">78</xref>
###xml 969 976 969 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1033 1036 1033 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B174">174</xref>
###xml 1048 1051 1048 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B174">174</xref>
###xml 1064 1067 1064 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B175">175</xref>
###xml 1080 1083 1080 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B176">176</xref>
###xml 1084 1087 1084 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B177">177</xref>
###xml 1128 1131 1128 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B117">117</xref>
###xml 1132 1135 1132 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B178">178</xref>
###xml 1174 1177 1174 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B179">179</xref>
###xml 1216 1219 1216 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B180">180</xref>
###xml 1288 1291 1288 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B181">181</xref>
###xml 1292 1295 1292 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B182">182</xref>
###xml 1365 1368 1365 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B174">174</xref>
###xml 1369 1372 1369 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B181">181</xref>
###xml 1373 1376 1373 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B182">182</xref>
###xml 1496 1499 1496 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B183">183</xref>
###xml 1644 1647 1644 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B184">184</xref>
###xml 1752 1755 1752 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B183">183</xref>
IMT is a benign malignancy of mesenchymal origin with a prominent inflammatory component consisting of plasma cells and lymphocytes [171]. Although IMT mostly affects young individuals, it can develop at all ages. First described in the lung, these 'inflammatory pseudotumours' were considered a post-inflammatory condition rather than a malignant process [172]. IMTs can manifest in almost any anatomical site [171], although they are most common in tissues such as the lung, abdomen and retroperitoneum [173]. In 1999, Griffin et al. [78] reported an association between the 2p23 chromosomal rearrangement and expression of ALK with IMTs; the first indication that IMTs, or a subpopulation of IMTs, were neoplastic in origin rather than reactive [78]. Further studies have confirmed the presence of several different ALK-fusion proteins in IMTs, all containing the kinase domain of ALK together with one of a variety of partner proteins responsible for dimerization (Table 1). Those fusion partners described to date are TMP3-ALK [174], TMP4-ALK[174], ATIC-ALK [175], CLTC-ALK [176,177], CARS (cysteinyl-tRNA synthetase)-ALK [117,178], RANBP2 (Ran-binding protein 2)-ALK [179] and SEC31L1 (SEC31 homologue A)-ALK [180]. In fact, 35-60% of all IMTs appear to exhibit ALK rearrangements [181,182], with ALK-positive IMTs preferentially affecting young individuals [174,181,182]. Interestingly, ALK-positive IMT reoccurs in approx. 50% of cases, although no metastasis was detected in this group [183]. This pattern of occurrence is similar to that noted for ALK-positive ALCL. Moreover the prognosis appears to be better for ALK-positive IMTs [184], as is the case for ALK-positive ALCL. However, no obvious ALCL prognostic factors correlate with IMT [183] and the difference between ALK-positive and ALK-negative IMTs is still unclear. Thus we do not presently understand the functional relevance and consequences of ALK signalling in ALK-positive IMT.
###end p 66
###begin title 67
NSCLC
###end title 67
###begin p 68
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B185">185</xref>
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B186">186</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B79">79</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B79">79</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 414 417 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B187">187</xref>
###xml 418 421 418 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B193">193</xref>
###xml 721 724 721 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B194">194</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 1218 1221 1218 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B195">195</xref>
###xml 1222 1225 1222 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B198">198</xref>
###xml 1417 1420 1417 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B142">142</xref>
###xml 1486 1489 1486 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B195">195</xref>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
###xml 1241 1245 <span type="species:ncbi:10090">mice</span>
Lung cancer is the most common cause of cancer death in the world. Of the annual 1.3 million cases worldwide, NSCLC accounts for approx. 80% of all lung cancers [185,186]. In 2007 a novel gene fusion between ALK and EML4 was reported in NSCLC [79,80]. Studies from over 1900 NSCLC cases suggest a frequency of EML4-ALK fusion in the range 0.1-7.9%, encompassing a number of different translocation variants [79,80,187-193]. Extrapolation would suggest that approx. 3.5% of all NSCLC cases contain an EML4-ALK translocation, equivalent to over 45000 patients worldwide. Furthermore, the EML4-ALK translocation seems to be uninfluenced by ethnic differences, in contrast with point mutations in the EGFR observed in NSCLC [194]. EML4 does not appear to be exclusive as the fusion partner for ALK in NSCLC, since Rikova et al. [80], also identified TFG as an ALK-fusion partner in one NSCLC sample [80]. Also unclear is the issue of whether EML4-ALK is causative in NSCLC, and whether EML4-ALK will be an effective clinical marker/therapeutic target. However, cells expressing oncogenic variants of ALK or EML4-ALK fusion proteins show reduced growth upon treatment with ALK inhibitors, such as PF-2341066 or NVP-TAE684 [195-198]. Furthermore, mice overexpressing EML4-ALK (variant 1) develop tumours with malignant characteristics, which are treatable with administration of a small specific ALK inhibitor, NVP-TAE684 [142], confirming the potent oncogenic activity of the fusion kinase [195].
###end p 68
###begin p 69
###xml 169 172 169 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B193">193</xref>
###xml 444 447 444 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B193">193</xref>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 435 442 <span type="species:ncbi:9606">patient</span>
Although an attractive diagnostic marker, some caution should be employed when considering EML4-ALK as a diagnostic marker for NSCLC. A recent study by Martelli et al. [193] observed a subset (7.5%) of EML4-ALK translocations in NSCLC samples from European patients. However, the presence of EML4-ALK was also detected in non-tumour lung samples, where the EML4-ALK transcript was not detected in matching tumour samples from the same patient [193]. This observation raises some important questions concerning the role of EML4-ALK in the development of NSCLC, and further work is required to clarify this important issue.
###end p 69
###begin title 70
ALK-positive DLBCL
###end title 70
###begin p 71
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B85">85</xref>
###xml 398 401 398 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B199">199</xref>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B170">170</xref>
###xml 689 692 689 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B199">199</xref>
###xml 693 696 693 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B202">202</xref>
###xml 896 899 896 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B203">203</xref>
###xml 900 903 900 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B204">204</xref>
###xml 1141 1144 1141 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B200">200</xref>
###xml 1292 1295 1292 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B140">140</xref>
###xml 1296 1299 1296 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B141">141</xref>
###xml 1388 1391 1388 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B170">170</xref>
Among diffuse DLBCLs there is an ALK-positive subpopulation, which shows features of plasmablastic morphology. ALK-positive DLBCL usually expresses markers such as EMA (epithelial membrane antigen), CD138 and cytoplasmic Ig, together with ALK. Furthermore, ALK-positive DLBCL lacks expression of B-cell markers (CD20, CD79a), the T-cell marker CD3 and is typically negative for CD30 expression [85,199]. To date, 41 cases of ALK-positive DLBCL have been reported, spanning all age groups and displaying an overall predominance in males (male/female ratio, 5:1). In addition, ALK-positive DLBCL is correlated with an aggressive clinical outcome as well as a poor response to treatment [170,199-202]. The most frequent chromosomal rearrangement in ALK-positive DLBCL is the t(2;17)(p23;q23) translocation which generates CLTLC-ALK, although a few cases of NPM-ALK fusions have also been described [203,204]. Recently, a third variant of DLBCL was reported with a cryptic insertion of the 3'-ALK sequence at chromosome 4q22-24, displaying immunohistochemical staining characteristic of a DLBCL and focal granular cytoplasmatic staining of ALK [200], although the ALK-fusion partner in this case has not been identified. As previously discussed NPM-ALK translocation induces activation of STAT3 [140,141], and this also seems to occur in CLTC-ALK-driven DLBCL, but not in ALK-negative DLBCL [170]. These observations again indicate a close connection between deregulated ALK and phosphorylation of STAT3, suggesting that STAT3 inhibitors might be useful therapies for DLBCL.
###end p 71
###begin title 72
Overexpression of ALK in cancer
###end title 72
###begin p 73
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B86">86</xref>
Several groups have examined overexpression of ALK in different tumour materials, reporting excessive ALK expression in thyroid carcinoma, NSCLC, breast cancer, melanoma, neuroblastoma, glioblastoma, astrocytoma, retinoblastoma, ewing sarcoma and rhabdomyosarcoma [58]. Besides these tumour types, ALK expression has also been described in leiomyosarcoma and malignant peripheral nerve sheath tumours, as well as malignant fibrous histocytoma [86]. Some of these, NSCLC, glioblastoma and neuroblastoma, have also been evaluated with respect to ALK activation. However, the significance of ALK overexpression in many of these cancer types is uncharacterized at the molecular level.
###end p 73
###begin p 74
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B86">86</xref>
In the case of rhabdomyosarcoma, leiomyosarcoma and malignant fibrous histocytomas, increased copy number of the chromosomal region 2p23 may lead to the overexpression of ALK [86].
###end p 74
###begin p 75
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 436 443 436 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 461 464 461 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B205">205</xref>
PTN has been reported to induce ALK phosphorylation and subsequent downstream PKB/Akt activation in glioblastoma. In agreement, glioblastoma cell lines depleted of ALK grow at a reduced rate compared with parental cell lines [55]. Similar observations have also been reported in U87MG glioblastoma cell lines stimulated with MK [45]. Combined targeting of ALK and PTN in U87 glioblastoma cells significantly impairs tumour growth in an In vivo xenograft model [205].
###end p 75
###begin p 76
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B84">84</xref>
###xml 380 383 380 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B206">206</xref>
###xml 384 387 384 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B207">207</xref>
###xml 498 501 498 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B208">208</xref>
###xml 612 614 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 719 721 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 212 217 <span type="species:ncbi:9606">human</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 487 496 <span type="species:ncbi:10090">nude mice</span>
###xml 591 596 <span type="species:ncbi:9606">human</span>
A clear role for ALK in breast cancer has not been firmly established; however, several lines of evidence suggest a role for ALK in this disease. First, ALK is strongly expressed in several different subtypes of human breast cancers, in a pattern not consistent with normal tissue [84]. Secondly, PTN, the proposed mammalian ALK ligand, is extensively expressed in breast cancer [206,207], and expression of truncated PTN in a human breast cancer cell line abrogates tumour formation in nude mice [208]. Thirdly, the PTN receptor RPTPbeta/zeta is strongly expressed in different subtypes of human breast cancer [61]. Taken together with the hypothesis that ALK is indirectly activated via PTN/RPTPbeta/zeta signalling [61], it is possible that ALK harbours oncogenic potential in breast cancer development.
###end p 76
###begin title 77
ALK gain-of-function mutations in neuroblastoma
###end title 77
###begin p 78
###xml 252 255 252 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B209">209</xref>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN</italic>
###xml 744 747 744 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B210">210</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B88">88</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B89">89</xref>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B90">90</xref>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B89">89</xref>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B90">90</xref>
###xml 964 971 <span type="species:ncbi:9606">patient</span>
Neuroblastoma is derived from neural crest cells of the sympaticoadrenal lineage and can therefore arise throughout the sympathetic nervous system. It is the most common solid tumour in childhood and accounts for 15% of all paediatric oncology deaths [209]. Neuroblastoma tumours show heterogeneous biological and clinical features and a subset may undergo spontaneous differentiation or regression with little or no therapy, whereas the majority are difficult to cure with current regimes. The most common genetic features of neuroblastoma are amplification of the proto-oncogene MYCN (v-Myc myelocytomatosis viral-related oncogene, neuroblastoma derived), deletions of parts of chromosome arms 1p and 11q, gain of parts of 17q and triploidy [210]. Expression of full-length ALK in neuroblastoma was first demonstrated in 2000 [88], and is supported by subsequent studies showing that the ALK locus is amplified in neuroblastoma cell lines, as well as in primary patient samples [89,90]. A physical association between ALK and ShcC has also been demonstrated [89]. In agreement, silencing of ALK in NB-39-nu and Nagai neuroblastoma cell lines results in the down-regulation of ShcC phosphorylation, as well as PKB/Akt activation, with concomitant apoptosis [90].
###end p 78
###begin p 79
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B96">96</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B93">93</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 293 300 293 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B93">93</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 820 827 820 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B94">94</xref>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 770 779 <span type="species:ncbi:10090">nude mice</span>
During 2008, five groundbreaking studies reported the presence of activating ALK mutations in both familiar [96,97] and sporadic [93-97] cases of neuroblastoma. Interestingly, all mutations (except one) are localized within the kinase domain of ALK and are assumed to be activating in nature (Table 2). Furthermore, neuroblastoma patients who are positive for ALK mutations appear to have a worse prognosis [93-97]. In line with an oncogenic role for ALK in neuroblastoma, a number of neuroblastoma cell lines were also shown to harbour activating ALK mutations, and knockdown of ALK in these cell lines resulted in an inhibition of proliferation [97]. Two of these activating ALK mutants, F1174L and K1062M, can indeed induce rapid formation of subcutaneous tumours in nude mice, thus displaying transforming potential In vivo [94].
###end p 79
###begin title 80
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Activating mutations within the ALK kinase domain in neuroblastoma patients
###end title 80
###begin p 81
The work described above highlights the relevance of understanding ALK-mediated signalling in a physiological context, since ALK ligands, as well as mutations in downstream ALK signalling pathway components, are obvious candidates with potential roles in the progression of neuroblastoma. The identification of a role for a drug targetable RTK, such as ALK in neuroblastoma development, provides a real hope for future therapeutic treatments for this devastating disease.
###end p 81
###begin title 82
MOUSE MODELS FOR ALK-DRIVEN ALCL
###end title 82
###begin p 83
###xml 89 97 89 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 227 234 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 278 281 278 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B211">211</xref>
###xml 282 285 282 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B212">212</xref>
###xml 454 457 454 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B213">213</xref>
###xml 522 525 522 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B160">160</xref>
###xml 549 552 549 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B214">214</xref>
###xml 777 780 777 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B215">215</xref>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
NPM-ALK has been established as the causative protein in ALCL by a number of groups both in vitro and In vivo. Bone marrow-expressing human NPM-ALK is able to induce lymphoid malignancies in lethally irradiated mice, providing In vivo support for NPM-ALK as an oncogenic agent [211,212]. Moreover, transgenic animals expressing NPM-ALK under the control of the CD4 promoter develop CD30-positive NPM-ALK T-cell lymphomas, as well as plasma cell tumours [213]. Utilization of the haematopoietic cell-specific Vav promoter [160] and the Lck promoter [214] to overexpress NPM-ALK in mice further confirm a role in the development of lymphomas. Additional strategies of investigating NPM-ALK in the development of ALCL using animal models have been reported and recently reviewed [215].
###end p 83
###begin title 84
POTENTIAL TREATMENT STRATEGIES FOR ALK-POSITIVE CANCERS
###end title 84
###begin p 85
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B216">216</xref>
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B217">217</xref>
###xml 390 393 390 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B218">218</xref>
###xml 394 397 394 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B219">219</xref>
###xml 471 474 471 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B220">220</xref>
###xml 555 558 555 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B221">221</xref>
###xml 559 562 559 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B223">223</xref>
###xml 725 728 725 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B224">224</xref>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
The development of tyrosine kinase inhibitors for use in cancer therapy has proven effective in several cases. Most well-known is Gleevec which targets the BCR-Abl (breakpoint cluster region-Abl) fusion protein in CML (chronic myeloid leukaemia) [216,217]. In addition to inactivating Abl, Gleevec also targets the c-Kit RTK, as well as the PDGFR (platelet-derived growth factor receptor) [218,219]. c-Kit is highly expressed in GISTs (gastrointestinal stromal tumours) [220] and clinical trials have established Gleevec as a treatment for GIST patients [221-223]. Other examples of RTK inhibitors are Gefitinib and Erlotinib, monoclonal antibodies which selectively inhibit EGFR (ErbB1), and are used in treatment of NSCLC [224].
###end p 85
###begin p 86
###xml 213 216 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B198">198</xref>
###xml 342 345 342 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B142">142</xref>
###xml 541 544 541 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B142">142</xref>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
A screen of more than 600 different human cancer-derived cell lines with the ALK inhibitor TAE684 identified a number of ALK-positive ALCL, neuroblastoma and NSCLC cell lines in which proliferation was inhibited [198]. TAE684 is a 5-chloro-2,4-diaminophenylpyrimidine which targets the ATP-binding pocket of ALK thereby blocking ATP binding [142]. Furthermore, administration of TAE684 in mice after injection of NPM-ALK-positive ALCL cells (Karpas 299 cell line) prevented development of disease and induced regression of pre-induced ALCL [142].
###end p 86
###begin p 87
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B95">95</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B95">95</xref>
Neuroblastoma cell lines harbouring different activating ALK mutations appear to respond differently to inhibition of ALK via the inhibitor TAE684. For example, the ALK mutant F1174L observed in SH-SY5Y and KELLY neuroblastoma cell lines is sensitive to TAE684, whereas the R1275W ALK mutant observed in the SMS-KCNR cell line is unaffected. ALK-silencing experiments in these cell lines support the previous inhibitor TAE684 results, since growth inhibition and increased apoptosis were noted in SH-SY5Y and KELLY cells, but not in SMS-KCNR cells [95,97]. It should be noted that these ALK mutants were also tested in a Ba/BF3 cells, where both mutants exhibited transforming ability and were sensitive to TAE684 [95]. The reasons behind this differential response to TAE684 are presently unclear, but may indicate differences in genetic background, or reflect complex genetic predispositions acquired by these cells.
###end p 87
###begin p 88
###xml 102 105 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B196">196</xref>
###xml 195 198 195 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B197">197</xref>
###xml 415 418 415 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B225">225</xref>
###xml 430 433 430 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B226">226</xref>
###xml 521 524 521 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B227">227</xref>
###xml 617 620 617 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B228">228</xref>
###xml 1003 1006 1003 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B229">229</xref>
###xml 1007 1010 1007 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B230">230</xref>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 489 496 <span type="species:ncbi:9606">patient</span>
###xml 674 682 <span type="species:ncbi:9606">patients</span>
An additional ALK inhibitor is PF-02341066, also an ATP competitor, which targets both c-Met and ALK [196]. PF-02341066 has been shown to reduce ALK-positive ALCL development in an animal model [197], and is currently in phase I trails for patients with advanced anaplastic large cell lymphomas (www.ClinicalTrials.gov). UCN-01 (unco-ordinated 1), a staurosporine derivative, which inhibits PKC (protein kinase C) [225] and chk1 [226], has been reported to cause disease regression in one patient with ALK-positive ALCL [227]. However, others have been unable to confirm a direct relationship between UCN-01 and ALK [228]. Presently a phase I clinical trial using UCN-01 in patients with relapsed or refractory systemic ALCL or mature T-cell lymphoma is underway (www.ClinicalTrials.gov). Although several PTK inhibitors are used successfully in the clinic, ALK inhibitors are not yet so well developed. This active area of research should hopefully produce effective and clinically relevant compounds [229,230].
###end p 88
###begin p 89
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 440 443 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B231">231</xref>
###xml 560 563 560 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B205">205</xref>
###xml 678 681 678 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B232">232</xref>
###xml 706 709 706 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B233">233</xref>
###xml 798 806 798 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 821 828 821 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 983 986 983 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B233">233</xref>
###xml 829 834 <span type="species:ncbi:10090">mouse</span>
Besides small-molecule chemical inhibitors, ALK has also been the target of a number of strategies aimed at reducing mRNA levels, thus depleting the ALK protein. In glioblastoma, PTN and ALK appear to be up-regulated and functionally relevant, since ALK and PTN ribozyme-expressing glioblastoma cell lines show reduced signalling potential. Moreover, in xenograft models, silencing of either ALK or PTN results in reduced tumour growth [55,231]. A double knockdown of PTN and ALK completely inhibited xenograft tumour growth over a 60-day experimental period [205]. Similar ribozyme-mediated silencing was observed for NPM-ALK in ALCL and Hodgkin's lymphoma-derived cell lines [232]. Finally, Piva et al. [233] have reported induction of cell death in ALK-positive ALCL cell lines by ALK silencing in vitro as well as in In vivo mouse models of ALCL tumour growth. In this case silencing was achieved by injection of adenovirus-expressing an shRNA (small hairpin RNA)-targeting ALK [233].
###end p 89
###begin p 90
###xml 272 275 272 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B234">234</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Interestingly, DNA vaccination of animals against human ALK prior to challenge with ALK-expressing lymphoma cells provides protection against disease. Furthermore, in already diseased animals ALK vaccination in combination with standard treatment increased the cure rate [234].
###end p 90
###begin p 91
###xml 553 556 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B235">235</xref>
###xml 852 855 852 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B132">132</xref>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
Although the direct targeting of ALK may be preferential for treatment of ALK-positive malignancies, other approaches may provide a beneficial complement. By targeting different ALK-interacting proteins, several reports have demonstrated reduced viability and tumour-forming capacity of NPM-ALK-positive cell lines. For example, NPM-ALK interacts with the chaperone Hsp90 (heat-shock protein 90), and inactivation of Hsp90 with 17-AAG (17-allyl-amino-demethoxygeldanamycin) results in degradation of NPM-ALK and subsequent apoptosis in ALCL cell lines [235]. Another example of possible downstream targets in ALK-positive ALCL is PKB/Akt. Injection of mice with cells expressing NPM-ALK, together with dominant-negative PKB/Akt results in a severely impaired tumour-forming capacity as compared with animals receiving control NPM-ALK-expressing cells [132].
###end p 91
###begin p 92
###xml 264 267 264 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B236">236</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B93">93</xref>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B97">97</xref>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
###xml 295 300 <span type="species:ncbi:9606">human</span>
Inhibitory antibodies are also a feasible alternative to small molecules. One such example is Trastuzumab (Herceptin), a monoclonal antibody, which binds to the extracellular juxtamembrane domain of HER2 and prolongs life in patients with human epithelial cancer [236]. Inhibitory antibodies to human ALK have been described, which reduce the level of phosphorylation of ALK, and consequently also the basal activity of MAPK in constitutively active ALK-expressing HEK-293 cells. Furthermore, these blocking antibodies are able to reduce the basal differentiation of ALK-transfected PC12 cells [32]. The authors suggest that this monoclonal antibody may function by blocking dimerization of ALK receptors, since stimulation with activating antibodies is abrogated by the inhibitory antibody. Whether this antibody indeed blocks ligand(s)-mediated receptor dimerization of ALK remains to be seen, and it is possible that this blocking antibody against ALK will display inhibitory activity towards the recently discovered activating ALK mutants in neuroblastoma [93-97]. Such blocking antibodies are potential therapeutics for cancers displaying overexpression or activating mutations of the full-length ALK RTK, and not the translocation-generated fusion oncogenes, and may indeed have the capacity to prolong life and increase the therapeutic effects of other treatments.
###end p 92
###begin title 93
OUTSTANDING QUESTIONS IN ALK RESEARCH: SPECULATION FOR THE FUTURE
###end title 93
###begin p 94
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 303 313 303 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 691 698 691 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1544 1548 1544 1548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1604</sup>
###xml 318 328 <span type="species:ncbi:7955">zebra fish</span>
###xml 1478 1483 <span type="species:ncbi:9606">human</span>
###xml 1581 1586 <span type="species:ncbi:10090">mouse</span>
One of the most disputed areas in the ALK research field at the present time is the issue of PTN and MK as ligands of ALK In vivo. To date, there is no genetic evidence to support this from model systems, in spite of the fact that a number of organisms in which ALK signalling has been studied (such as Drosophila and zebra fish) have clear homologues. The possibility exists that different ligands for ALK are utilized in different developmental processes, and that indeed PTN/MK function as ALK ligands, but that as yet unidentified 'Jeb-like' vertebrate ligands also exist. In the absence of 'Jeb-like' vertebrate ligands, the spatial and temporal relevance of the PTN/MK-ALK interaction In vivo needs to be addressed. The issue of ALK ligands is of particular relevance in neuroblastoma, since it follows that any misregulation of an ALK ligand may influence neuroblastoma progression even in the absence of activating ALK mutations. Structural information regarding ALK is also lacking, and would be an invaluable treasure trove of information. The unique organization of ALK in the extracellular region suggests that important information will be gleaned from solving the ALK structure, with or without PTN/MK. A simpler task would be elucidation of the crystal structure of the intracellular domain of ALK, in the presence or absence of inhibitors, or indeed in the active or inactive conformation. In this regard it would be important to consider crystallization of the human ALK in order to understand the relevance, if any, of the Tyr1604 residue which is lacking in the mouse ALK.
###end p 94
###begin p 95
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
Much work is ongoing concerning generation of specific ALK inhibitors, which would surely be simplified by intricate knowledge of the ALK kinase domain structure. This is an obvious area of importance to be pursued over the coming years. A number of different ALK inhibitors may be needed for therapeutic use, if the paradigm of BCR-Abl and CML inhibitors will also apply to ALK-driven neoplasms. Further development and exploration of monoclonal antibodies to ALK may also provide important therapeutic approaches, particularly in neuroblastoma, and potentially offers the opportunity to interrupt the interaction between ALK and its ligand(s) In vivo. While frustrating for those who have painstakingly developed and analysed the ALK-knockout mice, the lack of obvious phenotypes observed in these animals offers hope that side effects of ALK inhibition may be minimal.
###end p 95
###begin p 96
###xml 538 545 538 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 596 603 596 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 818 823 <span type="species:ncbi:9606">human</span>
Although a wealth of information exists concerning NPM-ALK signalling, it is less clear whether this information can be directly translated over to the many other ALK fusion proteins. Even less clear is the signalling mediated by the full-length ALK receptor. Further work will hopefully address these issues. We are currently unclear on the mechanisms of down-regulation of full-length ALK, and also of the physiological relevance of the different ALK cleavage products. The functional relevance of the potential ALK-dependence receptor In vivo also needs to be clarified. While considering the In vivo importance of the full-length ALK, it should be noted that RTK loss-of-function is often associated with developmental syndromes, and whereas no connection has been made to date, future work may implicate ALK in a human syndrome perhaps involving the nervous system.
###end p 96
###begin p 97
A large number of studies have identified ALK-interacting proteins as well as molecules which are transcriptionally modulated in response to ALK activation. Only a handful of these have been investigated in detail. The difficult task of functional characterization and identification of biologically and clinically relevant molecules in these data sets lies in the future. However, the value of these data sets will not be realised without corresponding biological context.
###end p 97
###begin p 98
###xml 175 184 175 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.elegans</italic>
###xml 186 196 186 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 175 184 <span type="species:ncbi:6239">C.elegans</span>
###xml 198 207 <span type="species:ncbi:7955">zebrafish</span>
###xml 212 217 <span type="species:ncbi:10090">mouse</span>
###xml 246 255 <span type="species:ncbi:7955">zebrafish</span>
Further insight into ALK function, in terms of signalling pathways and developmental context, may come from genetic screens and analysis in the model organism systems such as C.elegans, Drosophila, zebrafish and mouse. The function of the second zebrafish ALK family member is of interest, as is the question of a function for the MK/PTN homologues in the fruitfly.
###end p 98
###begin p 99
###xml 1010 1017 1010 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 116 122 <span type="species:ncbi:9606">humans</span>
###xml 880 885 <span type="species:ncbi:10090">mouse</span>
Many clinically relevant questions are also outstanding, such as whether ALK is capable of driving tumours alone in humans, or whether there are particular molecular partners that function with ALK in tumour progression. Difficult issues such as genetic predisposition seem to be especially important in neuroblastoma development. It is intriguing to consider why the ALK genetic locus is so sensitive to translocation events, and, in this regard, very little is known. Bearing in mind the recent gain-of-function ALK mutations in neuroblastoma, it is obvious to wonder whether these gain-of-function mutant ALK RTKs are ligand independent, either partially or completely. Furthermore, will we in the future find mutations in ALK ligands implicated in neuroblastoma progression? One area of research which we will most surely hear more of in the near future is the development of mouse models to investigate ALK-driven neuroblastoma, which will allow a deeper analysis of ALK action in neuroblastoma in a more In vivo context.
###end p 99
###begin title 100
CONCLUDING REMARKS
###end title 100
###begin p 101
###xml 490 497 490 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 725 732 <span type="species:ncbi:9606">patient</span>
###xml 756 764 <span type="species:ncbi:9606">patients</span>
###xml 768 776 <span type="species:ncbi:9606">children</span>
Currently, there are no clinically approved treatments for oncogenic malignancies caused by aberrant ALK activation that directly target ALK or the downstream ALK-activated signalling pathways. The accumulating body of work concerning ALK signal transduction pathways in both physiological and pathological states has provided a number of very real candidate targets for the development of clinical therapeutics. Outstanding questions surrounding the ALK ligand(s) and their mode of action In vivo are issues which need to be addressed. The future holds great hope for more tailoured therapeutic approaches for those suffering from ALK-driven cancers. Such ALK-directed treatments should benefit a number of different cancer patient populations, from ALCL patients to children with neuroblastoma, as well as NSCLC sufferers.
###end p 101
###begin title 102
ACKNOWLEDGEMENTS
###end title 102
###begin p 103
The authors would like to thank Margret Shirinian for comments and critical reading of the review prior to submission. We apologize to collegues whose work could not be cited owing to space limitations.
###end p 103
###begin title 104
FUNDING
###end title 104
###begin p 105
###xml 38 62 38 62 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="gs1">Swedish Research Council</funding-source>
###xml 77 90 77 90 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs1">621-2003-3399</award-id>
###xml 106 113 106 113 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs1">08-0597</award-id>
###xml 131 165 131 165 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="gs2">Swedish Cancer Research Foundation</funding-source>
###xml 180 186 180 186 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs2">07/959</award-id>
###xml 208 243 208 243 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="gs3">Swedish Childhood Cancer Foundation</funding-source>
###xml 258 264 258 264 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs3">08/074</award-id>
###xml 280 286 280 286 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs3">08/084</award-id>
The author's work is supported by the Swedish Research Council [grant number 621-2003-3399 (to R. H. P.), 08-0597 (to B. H.)]; the Swedish Cancer Research Foundation [grant number 07/959 (to B. H.)]; and the Swedish Childhood Cancer Foundation [grant number 08/074 (to R. H. P.), 08/084 (to B. H.)]. R. H. P. is a Swedish Cancer Foundation Research Fellow.
###end p 105
###begin article-title 106
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
###end article-title 106
###begin article-title 107
###xml 83 88 <span type="species:ncbi:9606">human</span>
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
###end article-title 107
###begin article-title 108
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
###end article-title 108
###begin article-title 109
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
###end article-title 109
###begin article-title 110
###xml 53 63 53 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 109 116 109 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 53 76 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation In vivo
###end article-title 110
###begin article-title 111
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin
###end article-title 111
###begin article-title 112
Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor
###end article-title 112
###begin article-title 113
Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module
###end article-title 113
###begin article-title 114
An adhesive domain detected in functionally diverse receptors
###end article-title 114
###begin article-title 115
###xml 97 120 97 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 97 120 <span type="species:ncbi:7227">Drosophila melanogaster</span>
A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster
###end article-title 115
###begin article-title 116
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity
###end article-title 116
###begin article-title 117
Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity
###end article-title 117
###begin article-title 118
Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase
###end article-title 118
###begin article-title 119
Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion
###end article-title 119
###begin article-title 120
Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers
###end article-title 120
###begin article-title 121
Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways [mili(Alk)] as receptor for Jeb signalling
###end article-title 121
###begin article-title 122
###xml 65 75 65 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
The formation of syncytia within the visceral musculature of the Drosophila midgut is dependent on duf, sns and mbc
###end article-title 122
###begin article-title 123
###xml 87 97 87 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
A distinct set of founders and fusion-competent myoblasts make visceral muscles in the Drosophila embryo
###end article-title 123
###begin article-title 124
###xml 15 25 15 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Jelly belly: a Drosophila LDL receptor repeat-containing signal required for mesoderm migration and differentiation
###end article-title 124
###begin article-title 125
###xml 62 72 62 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
The bHLH transcription factor Hand is regulated by Alk in the Drosophila embryonic gut
###end article-title 125
###begin article-title 126
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Drosophila anaplastic lymphoma kinase regulates Dpp signalling in the developing embryonic gut
###end article-title 126
###begin article-title 127
###xml 102 112 102 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila
###end article-title 127
###begin article-title 128
An SCF-like ubiquitin ligase complex that controls presynaptic differentiation
###end article-title 128
###begin article-title 129
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C elegans</italic>
C elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling
###end article-title 129
###begin article-title 130
###xml 101 123 101 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Caenorhabditis elegans</italic>
###xml 101 123 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
HEN-1, a secretory protein with an LDL receptor motif, regulates sensory integration and learning in Caenorhabditis elegans
###end article-title 130
###begin article-title 131
Leukocyte tyrosine kinase functions in pigment cell development
###end article-title 131
###begin article-title 132
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Characterization of the expression of the ALK receptor tyrosine kinase in mice
###end article-title 132
###begin article-title 133
Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system
###end article-title 133
###begin article-title 134
ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction
###end article-title 134
###begin article-title 135
Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
###end article-title 135
###begin article-title 136
Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway
###end article-title 136
###begin article-title 137
Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin
###end article-title 137
###begin article-title 138
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
###end article-title 138
###begin article-title 139
###xml 43 53 43 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 128 133 <span type="species:ncbi:10090">Mouse</span>
The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the Mouse ALK RTK
###end article-title 139
###begin article-title 140
Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells
###end article-title 140
###begin article-title 141
ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation
###end article-title 141
###begin article-title 142
Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation
###end article-title 142
###begin article-title 143
A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells
###end article-title 143
###begin article-title 144
Molecular cloning of the 18-kDa growth-associated protein of developing brain
###end article-title 144
###begin article-title 145
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
###xml 23 28 <span type="species:ncbi:9606">human</span>
Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblasts and brain tissues
###end article-title 145
###begin article-title 146
Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin
###end article-title 146
###begin article-title 147
Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins
###end article-title 147
###begin article-title 148
A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product
###end article-title 148
###begin article-title 149
###xml 65 70 <span type="species:ncbi:9031">chick</span>
Identification of a new heparin-binding protein localized within chick basement membranes
###end article-title 149
###begin article-title 150
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types
###end article-title 150
###begin article-title 151
Midkine and pleiotrophin in neural development and cancer
###end article-title 151
###begin article-title 152
Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis
###end article-title 152
###begin article-title 153
Pleiotrophin signals increased tyrosine phosphorylation of beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta
###end article-title 153
###begin article-title 154
6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)
###end article-title 154
###begin article-title 155
Expression of syndecan-1 and -3 during embryogenesis of the central nervous system in relation to binding with midkine
###end article-title 155
###begin article-title 156
Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3)
###end article-title 156
###begin article-title 157
LDL receptor-related protein as a component of the midkine receptor
###end article-title 157
###begin article-title 158
alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor
###end article-title 158
###begin article-title 159
Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase
###end article-title 159
###begin article-title 160
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth
###end article-title 160
###begin article-title 161
Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase
###end article-title 161
###begin article-title 162
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin
###end article-title 162
###begin article-title 163
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
###end article-title 163
###begin article-title 164
In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
###end article-title 164
###begin article-title 165
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage
###end article-title 165
###begin article-title 166
Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation
###end article-title 166
###begin article-title 167
###xml 20 26 <span type="species:ncbi:9913">bovine</span>
Characterization of bovine heparin-binding neurotrophic factor (HBNF): assignment of disulfide bonds
###end article-title 167
###begin article-title 168
Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule
###end article-title 168
###begin article-title 169
Heparin-binding growth-associated molecule contains two heparin-binding beta-sheet domains that are homologous to the thrombospondin type I repeat
###end article-title 169
###begin article-title 170
###xml 58 81 58 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 58 81 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Miple1 and miple2 encode a family of MK/PTN homologues in Drosophila melanogaster
###end article-title 170
###begin article-title 171
Anaplastic lymphoma kinase proteins in growth control and cancer
###end article-title 171
###begin article-title 172
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications
###end article-title 172
###begin article-title 173
###xml 119 125 <span type="species:ncbi:9606">infant</span>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour
###end article-title 173
###begin article-title 174
###xml 102 107 <span type="species:ncbi:10090">mouse</span>
Distinct expression of midkine and pleiotrophin in the spinal cord and placental tissues during early mouse development
###end article-title 174
###begin article-title 175
Localization of pleiotrophin and midkine in the postnatal developing cerebellum
###end article-title 175
###begin article-title 176
Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis
###end article-title 176
###begin article-title 177
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues
###end article-title 177
###begin article-title 178
Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/midkine developmental gene family
###end article-title 178
###begin article-title 179
###xml 22 26 <span type="species:ncbi:10090">mice</span>
Female infertility in mice deficient in midkine and pleiotrophin, which form a distinct family of growth factors
###end article-title 179
###begin article-title 180
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response
###end article-title 180
###begin article-title 181
The ltk receptor tyrosine kinase is expressed in pre-B lymphocytes and cerebral neurons and uses a non-AUG translational initiator
###end article-title 181
###begin article-title 182
Expression of a chimeric CSF1R-LTK mediates ligand-dependent neurite outgrowth
###end article-title 182
###begin article-title 183
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
###end article-title 183
###begin article-title 184
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
###end article-title 184
###begin article-title 185
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
###end article-title 185
###begin article-title 186
Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma
###end article-title 186
###begin article-title 187
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
###end article-title 187
###begin article-title 188
Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer
###end article-title 188
###begin article-title 189
###xml 65 70 <span type="species:ncbi:9606">human</span>
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer
###end article-title 189
###begin article-title 190
A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation
###end article-title 190
###begin article-title 191
Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases
###end article-title 191
###begin article-title 192
ALK protein expression in rhabdomyosarcomas
###end article-title 192
###begin article-title 193
Expression of the ALK tyrosine kinase gene in neuroblastoma
###end article-title 193
###begin article-title 194
Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines
###end article-title 194
###begin article-title 195
Biological role of anaplastic lymphoma kinase in neuroblastoma
###end article-title 195
###begin article-title 196
ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status
###end article-title 196
###begin article-title 197
Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases
###end article-title 197
###begin article-title 198
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
###end article-title 198
###begin article-title 199
Oncogenic mutations of ALK kinase in neuroblastoma
###end article-title 199
###begin article-title 200
Activating mutations in ALK provide a therapeutic target in neuroblastoma
###end article-title 200
###begin article-title 201
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
###end article-title 201
###begin article-title 202
Identification of ALK as a major familial neuroblastoma predisposition gene
###end article-title 202
###begin article-title 203
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
###end article-title 203
###begin article-title 204
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
###end article-title 204
###begin article-title 205
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Pathobiology of ALK+ anaplastic large-cell lymphoma
###end article-title 205
###begin article-title 206
WHO Classification of Tumours of Haematopoietic and Lymphiod Tissues
###end article-title 206
###begin article-title 207
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
ALK anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
###end article-title 207
###begin article-title 208
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
###end article-title 208
###begin article-title 209
Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity
###end article-title 209
###begin article-title 210
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
ALK+ lymphoma: clinico-pathological findings and outcome
###end article-title 210
###begin article-title 211
###xml 90 98 <span type="species:ncbi:9606">children</span>
Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology
###end article-title 211
###begin article-title 212
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma
###end article-title 212
###begin article-title 213
Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma
###end article-title 213
###begin article-title 214
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma
###end article-title 214
###begin article-title 215
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma
###end article-title 215
###begin article-title 216
Structure and function of the cell surface (tethered) mucins
###end article-title 216
###begin article-title 217
Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals
###end article-title 217
###begin article-title 218
The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells
###end article-title 218
###begin article-title 219
The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein
###end article-title 219
###begin article-title 220
Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)
###end article-title 220
###begin article-title 221
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
###end article-title 221
###begin article-title 222
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor
###end article-title 222
###begin article-title 223
Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity
###end article-title 223
###begin article-title 224
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
###end article-title 224
###begin article-title 225
Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma
###end article-title 225
###begin article-title 226
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
###end article-title 226
###begin article-title 227
Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
###end article-title 227
###begin article-title 228
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion
###end article-title 228
###begin article-title 229
Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
###end article-title 229
###begin article-title 230
A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
###end article-title 230
###begin article-title 231
ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
###end article-title 231
###begin article-title 232
Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma
###end article-title 232
###begin article-title 233
Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
###end article-title 233
###begin article-title 234
###xml 42 47 <span type="species:ncbi:9606">human</span>
Structure and functional relationships in human pur H
###end article-title 234
###begin article-title 235
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
###end article-title 235
###begin article-title 236
Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K
###end article-title 236
###begin article-title 237
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis
###end article-title 237
###begin article-title 238
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a
###end article-title 238
###begin article-title 239
Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma
###end article-title 239
###begin article-title 240
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
###end article-title 240
###begin article-title 241
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway
###end article-title 241
###begin article-title 242
Identification of NPM-ALK interacting proteins by tandem mass spectrometry
###end article-title 242
###begin article-title 243
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf
###end article-title 243
###begin article-title 244
Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma
###end article-title 244
###begin article-title 245
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
###end article-title 245
###begin article-title 246
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma
###end article-title 246
###begin article-title 247
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
###end article-title 247
###begin article-title 248
Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3
###end article-title 248
###begin article-title 249
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells
###end article-title 249
###begin article-title 250
Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma
###end article-title 250
###begin article-title 251
JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells
###end article-title 251
###begin article-title 252
Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma
###end article-title 252
###begin article-title 253
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells
###end article-title 253
###begin article-title 254
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma
###end article-title 254
###begin article-title 255
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
###end article-title 255
###begin article-title 256
Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma
###end article-title 256
###begin article-title 257
Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells
###end article-title 257
###begin article-title 258
STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression
###end article-title 258
###begin article-title 259
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation
###end article-title 259
###begin article-title 260
Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas
###end article-title 260
###begin article-title 261
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration
###end article-title 261
###begin article-title 262
Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity
###end article-title 262
###begin article-title 263
NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry
###end article-title 263
###begin article-title 264
Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)
###end article-title 264
###begin article-title 265
###xml 59 74 <span type="species:ncbi:10090">transgenic mice</span>
Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase
###end article-title 265
###begin article-title 266
NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/cJun signaling in anaplastic large cell lymphoma
###end article-title 266
###begin article-title 267
Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma
###end article-title 267
###begin article-title 268
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL
###end article-title 268
###begin article-title 269
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes
###end article-title 269
###begin article-title 270
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
###end article-title 270
###begin article-title 271
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
###end article-title 271
###begin article-title 272
Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma
###end article-title 272
###begin article-title 273
Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry
###end article-title 273
###begin article-title 274
Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells
###end article-title 274
###begin article-title 275
Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion
###end article-title 275
###begin article-title 276
Inflammatory myofibroblastic tumours: where are we now?
###end article-title 276
###begin article-title 277
Postinflammatory tumors of the lung; report of four cases simulating xanthoma, fibroma, or plasma cell tumor
###end article-title 277
###begin article-title 278
Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases
###end article-title 278
###begin article-title 279
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
###end article-title 279
###begin article-title 280
ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor
###end article-title 280
###begin article-title 281
RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors
###end article-title 281
###begin article-title 282
Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor
###end article-title 282
###begin article-title 283
Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor
###end article-title 283
###begin article-title 284
Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
###end article-title 284
###begin article-title 285
Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor
###end article-title 285
###begin article-title 286
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor
###end article-title 286
###begin article-title 287
Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study
###end article-title 287
###begin article-title 288
Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases
###end article-title 288
###begin article-title 289
Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis
###end article-title 289
###begin article-title 290
Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival
###end article-title 290
###begin article-title 291
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world
###end article-title 291
###begin article-title 292
EML4-ALK fusion lung cancer: a rare acquired event
###end article-title 292
###begin article-title 293
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
###end article-title 293
###begin article-title 294
EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers
###end article-title 294
###begin article-title 295
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas
###end article-title 295
###begin article-title 296
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
###end article-title 296
###begin article-title 297
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer
###end article-title 297
###begin article-title 298
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues
###end article-title 298
###begin article-title 299
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
###end article-title 299
###begin article-title 300
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
A mouse model for EML4-ALK-positive lung cancer
###end article-title 300
###begin article-title 301
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
###end article-title 301
###begin article-title 302
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
###end article-title 302
###begin article-title 303
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
###end article-title 303
###begin article-title 304
ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature
###end article-title 304
###begin article-title 305
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24
###end article-title 305
###begin article-title 306
ALK-positive diffuse large B-cell lymphoma: report of three cases
###end article-title 306
###begin article-title 307
[Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]
###end article-title 307
###begin article-title 308
ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases
###end article-title 308
###begin article-title 309
A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation
###end article-title 309
###begin article-title 310
Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK
###end article-title 310
###begin article-title 311
Midkine and pleiotrophin expression in normal and malignant breast tissue
###end article-title 311
###begin article-title 312
The potential role of the heparin-binding growth factor pleiotrophin in breast cancer
###end article-title 312
###begin article-title 313
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer growth inhibited In vivo by a dominant negative pleiotrophin mutant
###end article-title 313
###begin article-title 314
Neuroblastoma
###end article-title 314
###begin article-title 315
Neuroblastoma: biological insights into a clinical enigma
###end article-title 315
###begin article-title 316
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice
###end article-title 316
###begin article-title 317
###xml 81 96 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice
###end article-title 317
###begin article-title 318
###xml 8 23 <span type="species:ncbi:10090">transgenic mice</span>
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
###end article-title 318
###begin article-title 319
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas
###end article-title 319
###begin article-title 320
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
###end article-title 320
###begin article-title 321
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
###end article-title 321
###begin article-title 322
Translation of the Philadelphia chromosome into therapy for CML
###end article-title 322
###begin article-title 323
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
###end article-title 323
###begin article-title 324
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
###end article-title 324
###begin article-title 325
###xml 39 44 <span type="species:ncbi:9606">human</span>
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
###end article-title 325
###begin article-title 326
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
###end article-title 326
###begin article-title 327
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
###end article-title 327
###begin article-title 328
###xml 52 59 <span type="species:ncbi:9606">patient</span>
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
###end article-title 328
###begin article-title 329
Role of tyrosine kinase inhibitors in cancer therapy
###end article-title 329
###begin article-title 330
UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities
###end article-title 330
###begin article-title 331
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
###end article-title 331
###begin article-title 332
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
###end article-title 332
###begin article-title 333
An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase
###end article-title 333
###begin article-title 334
Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase
###end article-title 334
###begin article-title 335
Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy
###end article-title 335
###begin article-title 336
Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma
###end article-title 336
###begin article-title 337
Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma
###end article-title 337
###begin article-title 338
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
###end article-title 338
###begin article-title 339
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
###end article-title 339
###begin article-title 340
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK+ CD30+ lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin
###end article-title 340
###begin article-title 341
Trastuzumab: mechanism of action and use in clinical practice
###end article-title 341
###begin article-title 342
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma
###end article-title 342

